Lymphoma & Myeloma Clinical Trials
Last Updated: 05/15/2020
CAR T/Cellular Therapy
Lymphoma CAR T/Cellular Therapy
Newly Diagnosed
2018-0580 (ZUMA-12): A Phase 2 Multicenter Study Evaluating the Efficacy and Safety of Axicabtagene Ciloleucel as First-Line Therapy in Subjects with High-Risk Large B-Cell Lymphoma (ZUMA-12)
Previously Treated
2019-0940 (Zuma 18): A Multicenter, Open-label, Expanded Access Study of KTE-X19 for the Treatment of Subjects with Relapsed/Refractory B-Cell Malignancies
2019-0776 (PBCAR20A): A Phase 1/2a, Open-label, Dose-escalation, Dose-expansion, Parallel Assignment Study to Evaluate the Safety and Clinical Activity of PBCAR20A in Study Participants with Relapsed/Refractory (r/r) Non-Hodgkin Lymphoma (NHL) or r/r Chronic Lymphocytic Leukemia (CLL) or Small Lymphocytic Lymphoma (SLL)
2019-0144 (JCAR017 to SOC): A Global Randomized Multicenter Phase 3 Trial to Compare the Efficacy and Safety of JCAR017 to Standard of Care in Adult Subjects with High Risk Transplant Eligible Relapse
2019-0133 (ZUMA 14): Phase 2 multicenter study of axi-cel with either rituximab or lenalidomide in r/r DLBCL (ZUMA-14)
2018-1134 (LOXO-305): A Phase 1/2 Study of Oral LOXO-305 in Patients with Previously Treated Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma (CLL/SLL) or Non-Hodgkin's Lymphoma (NHL)
2018-1049 (ALLO-501): Phase I/II study of ALLO-501, an anti-CD19 allogeneic CAR T cell therapy in patients with relapsed/refractory large B-cell lymphoma or follicular lymphoma
2017-0730 ( JCAR017): An Exploratory Phase 1/2 Trial To Evaluate The Safety And Efficacy Of JCAR017 Combinations In Subjects With Relapsed/Refractory B-Cell Malignancies (PLATFORM)
2017-0699 (ZUMA-7): A Phase 3, Randomized, Open-Label Study Evaluating the Efficacy of Axicabtagene Ciloleucel versus Standard of Care Therapy in Subjects with Relapsed/Refractory Diffuse Large B Cell Lymphoma (ZUMA-7)
2018-0373 (UNUM): Phase 1 Study of ACTR707, an Autologous T Cell Product, in Combination with Rituximab, in Subjects with Relapsed or Refractory CD20+ B Cell Lymphoma
2017-0161 (ZUMA-9): A Multicenter, Open-Label, Expanded Access Study of Axicabtagene Ciloleucel For The Treatment of Relapsed/Refractory Transplant-Ineligible Aggressive Non-Hodgkin Lymphoma (NHL)
2017-0055 (ZUMA-5): A Phase 2 Multicenter Study of axicabtagene ciloleucel in subjects with relapsed/refractory indolent non-hodgkin lymphoma
2015-0529 (CAR T-cells): Phase 1, Multicenter, Open-Label Study of JCAR017, CD19-targeted Chimeric Antigen Receptor (CAR) T Cells, for Relapsed and Refractory (R/R) B-cell Non-Hodgkin Lymphoma (NHL)
2015-0372 (KTE-C19): Phase 2 Multicenter Study Evaluating the Efficacy of KTE-C19 in Subjects with Relapsed/Refractory Mantle Cell Lymphoma (r/r MCL)
Myeloma CAR T/Cell Therapy
Previously Treated
2018-0639 (KarMMA-3 BB2121): A Phase 3 Multicenter, Randomized, Open-Label Study to Compare Efficacy and Safety of BB2121 vs DARATUMUMAB (DARA) IN COMBINATION WITH POMALIDOMIDE (POM) AND LOW-DOSE DEXAMETHASONE (DEX) (DPd) IN SUBJECTS WITH RELAPSED AND REFRACTORY MULTIPLE MYELOMA (RRMM) (KarMMa-3)
2018-0572 (KarMMa-2): A Phase 2, Multicohort, Open-label, Multicenter Study to Determine the Efficacy and Safety of bb2121 in Subjects with Relapsed and Refractory Multiple Myeloma and in Subjects With High-Risk Multiple Myeloma Having Progressed Within One Year of Initial Treatment (KarMMa-2)
2017-1012 (AMG701): A Phase 1 Open-label Study Evaluating the Safety, Tolerability, Pharmacokinetics, Pharmacodynamics, and Efficacy of AMG 701 in Subjects With Multiple Myeloma
2017-0494 (UCARTCS1): Phase I, Open Label Dose-Escalation Study to Evaluate the Safety, Expansion, Persistence and Clinical Activity of A Single Dose of UCARTCS1 (Allogeneic Engineered T-Cells Expressing Anti-CS1 Chimeric Antigen Receptor), Administered In Patients with Relapse
2017-0444 (P-BCMA-101): Open-Label, Multicenter, Single Ascending Dose Study to Assess the Safety of P-BCMA-101 in Subjects with Relapsed and/or Refractory Multiple Myeloma (MM)
Lymphoma Clinical Trials
Indolent Lymphoma (Follicular, Marginal Zone, Small Lymphocytic Leukemia)
Newly Diagnosed
2017-0859 (ILyAD Vit D): A Phase III Double Blind, Prospective Randomized Trial to Evaluate the Supplemental Effect of Vitamin D (Cholecalciferol) on Progression-Free Survival in Patients with Low Tumor-Burden Indolent Non-Hodgkin Lymphoma Treated with Rituximab Therapy
2017-0064 (ibrutinib + rituximab): Phase 3 Study of Ibrutinib with Rituximab versus Placebo in Combination with Rituximab in Treatment Naïve Subjects with Follicular Lymphoma
Previously Treated
2019-0644 (IGM-2323): Phase 1 Open-label, Multicenter Study Evaluating the Safety and Pharmacokinetics of Escalating Doses of IGM-2323 in Subjects with Relapsed/Refractory Non-Hodgkin Lymphomas
2019-0441 (Imbrella B): An open label, multicenter extension study in patients previously enrolled in a Genentech and/or F. Hoffmann-La Roche Ltd Sponsored Atezolizumab Study (Imbrella B)
2019-0313 (CG-806): A Phase 1 a/b Trial to Evaluate the Safety and Tolerability of CG-806 in Patients with CLL/SLL or Non-Hodgkin's Lymphomas
2019-0123 (HMPL-523): A Phase I, Open-Label Study to Evaluate the Safety, Tolerability, Pharmacokinetics, and Preliminary Efficacy of HMPL-523 in Patients with Relapsed or Refractory Lymphoma
2018-1160 (CC-99282): A Phase I, Multi-Center, Open Label Study to Assess the Safety, Pharmacokinetics, and Preliminary Efficacy of an Orally Available Small Molecule, CC-99282, Alone and in Combination with Rituximab in Subjects with Relapsed or Refractory Non-Hodgkins Lymphoma
2018-0996 (VLS-101): A Phase 1 dose-escalation and cohort-expansion study of VLS-101 in subjects with Hematological Malignancies
2017-1063 (LAM-002A): A Phase 1 Dose Escalation Study of the Safety and Pharmacokinetics of LAM-002A (apilimod dimesylate capsules) Administered Orally in Subjects with Relapsed or Refractory B-cell Non-Hodgkin Lymphoma
2017-1007 (BGB311): An International, Phase 2, Open-Label, Randomized Study of BGB-3111 Combined with Obinutuzumab Compared With Obinutuzumab Monotherapy in Relapsed/Refractory Follicular Lymphoma
2017-0440 (UBL+TGR-1202): A Phase 2b Randomized Study to Assess the Efficacy and Safety of the Combinationof Ublituximab + TGR-1202 with or without Bendamustine and TGR-1202 alone inPatients with Previously Treated Non-Hodgkin Lymphoma
2017-0141 (BTCT4465): An Open-label, Multicenter, Phase I/Ib Trial Evaluating the Safety and Pharmacokinetics of Escalating Doses of BTCT4465A as a Single Agent and Combined with Atezolizumab in Patients with Relapsed or Refractory B-Cell Non-Hodgkin Lymphoma And Chronic Lymphocytic Leukemia
2015-0464 (obinutuzmab + lenalidomide): An Open Label, Phase 2 study of Obinutuzumab and Lenalidomide in Previously Untreated Subjects with Follicular Lymphoma
2014-0541 (Phase 1b/2): An Open-label, Phase 1b/2 Study of Acalabrutinib Alone or in Combination Therapy in Subjects with B-cell Non-Hodgkin Lymphoma
2014-0539 (ACP-196): Phase II study of rituximab plus pembrolizumab (MK-3475) in subjects with relapsed follicular lymphoma
2013-0261 (Len+ Obinutuzumab): Phase I/II study of Lenalidomide and Obinutuzumab (GA101) in Relapsed Indolent Non-Hodgkin Lymphoma
Diffuse Large B-Cell Lymphoma
Newly Diagnosed
2018-0817 (Mosunetuzumab): A Phase Ib/II, Open-Label, Multicenter, Randomized, Controlled Study Investigating the Safety, Tolerability, Pharmacokinetics, and Efficacy of MOSUNETUZUMAB (BTCT4465A) in Combination with CHOP or CHPPOLATUZUMAB VEDOTIN in Patients with BCell NHL
2015-0147 (Smart Start): Phase I/II Study of Lenalidomide and Obinutuzumab with CHOP for Diffuse Large B Cell Lymphoma
Previously Treated
2019-0644 (IGM-2323): Phase 1 Open-label, Multicenter Study Evaluating the Safety and Pharmacokinetics of Escalating Doses of IGM-2323 in Subjects with Relapsed/Refractory Non-Hodgkin Lymphomas
2019-0605 (CPI-613): A Phase II Clinical Trial of CPI-613 in Patients with Relapsed or Refractory Burkitt Lymphoma/Leukemia or high-grade B-cell lymphoma with rearrangements of MYC and BCL2 and/or BCL6
2019-0184 (Fimepinostat): Phase 1/2 Open Label, Multi-center, Dose-Escalation Study to Assess the Safety, Tolerability and Pharmacokinetics of Orally Administered Fimepinostat (CUDC-907) a PI3K and HDAC Inhibitor, in Subjects with Relapsed and/or Refractory Lymphoma
2019-0123 (HMPL-523): A Phase I, Open-Label Study to Evaluate the Safety, Tolerability, Pharmacokinetics, and Preliminary Efficacy of HMPL-523 in Patients with Relapsed or Refractory Lymphoma
2018-1160 (CC-99282): A Phase I, Multi-Center, Open Label Study to Assess the Safety, Pharmacokinetics, and Preliminary Efficacy of an Orally Available Small Molecule, CC-99282, Alone and in Combination with Rituximab in Subjects with Relapsed or Refractory Non-Hodgkins Lymphoma
2018-0999 (Hu5F9-G4): A Phase 1b/2 Trial of Hu5F9 G4 in Combination with Rituximab in Patients with Relapsed/Refractory B-Cell Non-Hodgkin's Lymphoma
2018-0996 (VLS-101): A Phase 1 dose-escalation and cohort-expansion study of VLS-101 in subjects with Hematological Malignancies
2018-0510 (NIVO): Nivolumab and Ibrutinib for Relapsed or Refractory Central Nervous System Lymphoma
2017-1063 (LAM-002A): A Phase 1 Dose Escalation Study of the Safety and Pharmacokinetics of LAM-002A (apilimod dimesylate capsules) Administered Orally in Subjects with Relapsed or Refractory B-cell Non-Hodgkin Lymphoma
2017-0626 (ASTX660): Phase 1-2 Study of the Safety, Pharmacokinetics, and Preliminary Activity of ASTX660 in Subjects with Advanced Solid Tumors and Lymphomas
2017-0475 (UC-961): A Phase 1b-2 Study of the ROR1-Targeting Monoclonal Antibody, Cirmtuzumab (UC-961), and the Bruton Tyrosine Kinase Inhibitor, Ibrutinib, in Patients with B-Cell Lymphoid Malignancies
2017-0141 (BTCT4465): An Open-label, Multicenter, Phase 1 Trial Evaluating the Safety and Pharmacokinetics of Escalating Doses of BTCT4465A, With or Without Single-dose Obinutuzumab Pre-treatment, in Patients with Relapsed or Refractory B-Cell Non-Hodgkin's Lymphoma And Chronic Lymphocytic Leukemia
2017-0025 (DA-EPOCH): Phase I Study of Venetoclax plus DA-EPOCH-R for the Treatment of Aggressive B-Cell Lymphomas
2015-0569 (Based CD19): Long Term Follow-Up of Patients Exposed to Lentiviral- Based CD19 directed CART Cell Therapy
2015-0022 ( DLBCL): Pilot Project for Creation of the DLBCL Response Prediction Model: Combining Early Interim Functional Imaging, Detection Of A Tumor-Specific Clonotype and Metabolic Profiling of Blood Of In Patients With Relapsed/Refractory Diffuse Large B-cell Lymphoma To Predict Response To Standard Immunochemotherapy
2014-0539 (ACP-196): Phase II Study of Rituximab Plus Pembrolizumab (MK-3475) In Subjects with Relapsed Follicular Lymphoma
Hodgkin Lymphoma
Newly Diagnosed
2018-1061 (Propsylaxis): A Single Cohort Phase 4 Trial Investigating the Impact of G-CSF Primary Prophylaxis for Advanced Stage Hodgkin Lymphoma Patients Treated with A+AVD4
2018-0114 (PET-AVD): A Phase II Trial of PET-Directed Therapy using AVD (doxorubicin, vinblastine, and dacarbazine) plus Brentuximab Vedotin Induction Chemotherapy, with or without Brentuximab Vedotin plus Nivolumab, Followed by Nivolumab Consolidation for Patients with Previously Untreated Non-bulky Limited Stage Hodgkin Lymphoma
Previously Treated
2019-0123 (HMPL-523): A Phase I, Open-Label Study to Evaluate the Safety, Tolerability, Pharmacokinetics, and Preliminary Efficacy of HMPL-523 in Patients with Relapsed or Refractory Lymphoma
2017-0974 (CheckMate 812): Randomized, Open-label, Phase 3 Trial of Nivolumab plus Brentuximab vedotin versus Brentuximab vedotin alone in Participants with Relapsed Refractory or Ineligible for Autologous Stem Cell Transplant (ASCT) Advanced Stage Classical Hodgkin Lymphoma (CheckMate 812: CHECKpoint pathway and nivoluMAb clinical Trial Evaluation 812)
2017-0731 (PD-1 + ICE): A phase II trial of response-adapted second-line therapy for Hodgkin lymphoma using anti-PD-1 antibody nivolumab +/- ICE chemotherapy as a bridge to autologous hematopoietic cell transplant (NICE Trial)
2016-0896 (BTK, Ibrutinib): A Phase II Multicenter Single Arm Study to Evaluate the Efficacy and Safety of Single Agent Bruton's Tyrosine Kinase Inhibitor, Ibrutinib, in Patients with Relapsed Refractory Classical Hodgkin's Lymphoma
2016-0423 (Nivo +Brent): Phase II, Multi-center Trial of Nivolumab and Brentuximab Vedotin in Patients with Untreated Hodgkin Lymphoma Over the Age of 60 Years or Unable to Receive Standard Adriamycin, Bleomycin, Vinblastine and Dacarbazine (ABVD) Chemotherapy
Mantle Cell Lymphoma
Newly Diagnosed
2018-0447 (Young MCL Pts): A Phase II Study of Ibrutinib plus Rituximab followed by Venetoclax and Hyper-CVAD Consolidation in Newly Diagnosed Young Patients with Mantle Cell Lymphoma: Window II Protocol
2016-1048 (ACP-196): A Phase 3, Randomized, Double-blind, Placebo-controlled, Multicenter Study of Bendamustine and Rituximab (BR) Alone Verses in Combination with Acalabrutinib (ACP-196) in Subjects With Previously Untreated Mantle Cell Lymphoma
Previously Treated
2019-0123 (HMPL-523): A Phase I, Open-Label Study to Evaluate the Safety, Tolerability, Pharmacokinetics, and Preliminary Efficacy of HMPL-523 in Patients with Relapsed or Refractory Lymphoma
2018-1160 (CC-99282): A Phase I, Multi-Center, Open Label Study to Assess the Safety, Pharmacokinetics, and Preliminary Efficacy of an Orally Available Small Molecule, CC-99282, Alone and in Combination with Rituximab in Subjects with Relapsed or Refractory Non-Hodgkins Lymphoma
2018-1090 (Ixazomib/Rituximab): A Phase 2 Study of Ixazomib and Rituximab in Bruton Tyrosine Kinase Inhibitor Resistant Mantle Cell Lymphoma
2018-0996 (VLS-101): A Phase 1 dose-escalation and cohort-expansion study of VLS-101 in subjects with Hematological Malignancies
2018-0935 (Venetoclax & Acalabrutinib): An open label, Phase II investigator initiated study of venetoclax and acalabrutinib in previously treated relapsed/refractory patients with mantle cell lymphoma (MCL)
2017-0475 (UC-961): A Phase 1b-2 Study of the ROR1-Targeting Monoclonal Antibody, Cirmtuzumab (UC-961), and the Bruton Tyrosine Kinase Inhibitor, Ibrutinib, in Patients with B-Cell Lymphoid Malignancies
2017-0440 (UBL+TGR+1202): A Phase 2b Randomized Study to Assess the Efficacy and Safety of the Combination of Ublituximab + TGR-1202 with or without Bendamustine and TGR-1202 alone in Patients with Previously Treated Non-Hodgkin?s Lymphoma
2017-0051 (PDX): A Pilot Study Evaluating Xenografts to Personalize Therapies (PDX) in Relapsed Mantle Cell Lymphoma to Optimize Response: The EXPLORE trial
2017-0301 (AZD5991): A Phase 1, Open-Label, Multicentre Study to Assess the Safety, Tolerability, Pharmacokinetics and Preliminary Antitumor Activity of Ascending Doses of AZD5991 in Subjects with Relapsed or Refractory Haematologic Malignancies
2017-0238 (Ibrutinib + Venetoclax): Phase 3 Study of Ibrutinib in Combination with Venetoclax in Subjects with
2016-0024 (ACP-196): A Phase 1b, Multicenter, Open-label Study of ACP-196 in Combination with Bendamustine and Rituximab (BR) in Subjects with Mantle Cell Lymphoma
2015-0663 (BGB-3111): A Phase I, Open-Label, Multiple-Dose, Dose Escalation and Expansion Study to Investigate the Safety and Pharmacokinetics of the BTK Inhibitor BGB-3111 in Subjects with B-Cell Lymphoid Malignancies
2014-0559 (Rit+H-CVAD): A Phase II Study of Ibrutinib plus Rituximab with Hyper-CVAD Consolidation in Newly Diagnosed Young Patients with Mantle Cell Lymphoma: A Window Period for Bioimmunotherapy before Chemotherapy
2014-0630 (ONC201): Phase I/II Study of Oral ONC201 in Patients with Relapsed/Refractory Non-Hodgkin Lymphoma
2013-0090 (Ibrutinib + Rituximab): A Phase II Study of Ibrutinib Plus Rituximab in Patients with Relapsed/Refractory Mantle Cell Lymphoma
2012-1107 (2010-0837) (PCI-32765): Phase 3b, Multicenter, Open-label, PCI-32765 (Ibrutinib) Long-term Extension Study
Burkitt's Lymphoma
Newly Diagnosed
2018-0817 (Mosunetuzumab): A Phase Ib/II, Open-Label, Multicenter, Randomized, Controlled Study Investigating the Safety, Tolerability, Pharmacokinetics, and Efficacy of MOSUNETUZUMAB (BTCT4465A) in Combination with CHOP or CHPPOLATUZUMAB VEDOTIN in Patients with BCell NHL
Previously Treated
2019-0644 (IGM-2323): Phase 1 Open-label, Multicenter Study Evaluating the Safety and Pharmacokinetics of Escalating Doses of IGM-2323 in Subjects with Relapsed/Refractory Non-Hodgkin Lymphomas
2019-0605 (CPI-613): A Phase II Clinical Trial of CPI-613 in Patients with Relapsed or Refractory Burkitt Lymphoma/Leukemia or high-grade B-cell lymphoma with rearrangements of MYC and BCL2 and/or BCL6
2019-0313 (CG-806): A Phase 1 a/b Trial to Evaluate the Safety and Tolerability of CG-806 in Patients with CLL/SLL or Non-Hodgkin's Lymphomas
2019-0123 (HMPL-523): A Phase I, Open-Label Study to Evaluate the Safety, Tolerability, Pharmacokinetics, and Preliminary Efficacy of HMPL-523 in Patients with Relapsed or Refractory Lymphoma
2019-0184 (Fimepinostat): Phase 1/2 Open Label, Multi-center, Dose-Escalation Study to Assess the Safety, Tolerability and Pharmacokinetics of Orally Administered Fimepinostat (CUDC-907) a PI3K and HDAC Inhibitor, in Subjects with Relapsed and/or Refractory Lymphoma
2018-1160 (CC-99282): A Phase I, Multi-Center, Open Label Study to Assess the Safety, Pharmacokinetics, and Preliminary Efficacy of an Orally Available Small Molecule, CC-99282, Alone and in Combination with Rituximab in Subjects with Relapsed or Refractory Non-Hodgkins Lymphoma
2018-0999 (Hu5F9): A Phase 1b/2 Trial of Hu5F9 G4 in Combination with Rituximab in Patients with Relapsed/Refractory B-Cell Non-Hodgkin's Lymphoma
2018-0996 (VLS-101): A Phase 1 dose-escalation and cohort-expansion study of VLS-101 in subjects with Hematological Malignancies
2018-0510 (NIVO): Nivolumab and Ibrutinib for Relapsed or Refractory Central Nervous System Lymphoma
2017-0475 (UC-961): A Phase 1b-2 Study of the ROR1-Targeting Monoclonal Antibody, Cirmtuzumab (UC-961), and the Bruton Tyrosine Kinase Inhibitor, Ibrutinib, in Patients with B-Cell Lymphoid Malignancies
2017-0141 (BTCT4465): An Open-label, Multicenter, Phase 1 Trial Evaluating the Safety and Pharmacokinetics of Escalating Doses of BTCT4465A, With or Without Single-dose Obinutuzumab Pre-treatment, in Patients with Relapsed or Refractory B-Cell Non-Hodgkin's Lymphoma And Chronic Lymphocytic Leukemia
2014-0539 (ACP-196): Phase II Study of Rituximab Plus Pembrolizumab (MK-3475) In Subjects with Relapsed Follicular Lymphoma
Peripheral T-Cell Lymphoma
Newly Diagnosed
2017-0927 (CD30+ PTCL): A Phase 2 Study of Brentuximab Vedotin Plus Cyclophosphamide, Doxorubicin, Etoposide, and Prednisone (CHEP-BV) Followed by BV Consolidation in Patients with CD30-Positive Peripheral T-cell Lymphomas
2015-0555 (Folotyn®): Phase 1, Dose-Finding Study of Folotyn® (Pralatrexate Injection) Plus Cyclophosphamide, Doxorubicin, Vincristine, and Prednisone (CHOP) in Patients with Peripheral T-Cell Lymphoma (PTCL)
2013-0367 Concurrent Chemotherapy and Radiation Therapy for Newly Diagnosed Patients with Stage I/II Nasal NK Cell Lymphoma
Previously Treated
2019-0755 (REDIRECT): A Phase II Open-label Multicenter Study to Assess the Efficacy and Safety of AFM13 in Patients with Relapsed or Refractory CD30-positive Peripheral T-cell Lymphoma or Transformed Mycosis Fungoides (REDIRECT)
2018-1064 (TTI-622): A Phase 1a/1b Dose Escalation and Expansion Trial of TTI-622 in Patients with Advance Relapsed or Refractory Lymphoma or Myeloma
2018-0908 (Tenalisib): A Phase I/IIa Study of Tenaslisib in Combination with Romidepsin in R/R TCL
2017-0927 (CHEP-BV): A Phase 2 Study of Brentuximab Vedotin Plus Cyclophosphamide, Doxorubicin, Etoposide, and Prednisone (CHEP-BV) Followed by BV Consolidation in Patients with CD30-Positive Peripheral T-cell Lymphomas
2017-0626 (ASTX660): Phase 1-2 Study of the Safety, Pharmacokinetics, and Preliminary Activity of ASTX660 in Subjects with Advanced Solid Tumors and Lymphomas
2017-0272 (MK-3475): A phase I/II study of pembrolizumab (MK-3475) in combination with romidepsin in patients with relapsed or refractory peripheral T-cell lymphoma
Multiple Myeloma Clinical Trials
Myeloma CAR T/Cellular Therapy
Myeloma
Newly Diagnosed
2019-0556 (TAK-079): An Open-Label, Multicenter Phase 1b Study Investigating the Safety of TAK-079 in Combination With Backbone Regimens for the Treatment of Patients With Newly Diagnosed Multiple Myeloma and for Whom Stem Cell Transplantation Is Not Planned as Initial Therapy
2019-0304 (NDMM): A Randomized Study of Daratumumab Plus Lenalidomide Versus Lenalidomide Alone as Maintenance Treatment in Patients with Newly Diagnosed Multiple Myeloma Who Are Minimal Residual Disease Positive After Frontline Autologous Stem Cell Transplant
2018-0345 (Vaccine in SMM): A Personalized Vaccine for the Immune Prevention of Multiple Myeloma
Previously Treated
2019-0945 (REGN5459): A Phase 1/2 FIH Study of REGN5459 (Anti-BCMA x Anti CD3 Bispecific Antibody) in Patients with Relapsed or Refractory Multiple Myeloma
2018-0512 (D+B-Dex in R/R MM): A Phase 2 Study of Daratumumab, Bortezomab and Dexamethasone followed by Daratumumab, Ixaazomib, and Dexamethasone for Relapsed/Refractory Myeloma
2018-0369 (DREAMM 2): A Phase II, Open Label, Randomized, Two-Arm Study to Investigate the Efficacy and Safety of Two Doses of the Antibody Drug Conjugate GSK2857916 in Participants with Multiple Myeloma Who Had 3 or More Prior Lines of Treatment, Are Refractory to a Proteasome Inhibitor and an Immunomodulatory Agent and Have Failed an Anti-CD38 Antibody (DREAMM 2)
2018-0285 (Ventelocla): A Phase 3, Multicenter, Randomized, Open Label Study of Venetoclax and Dexamethasone Compared with Pomalidomide and Dexamethasone in Subjects with t(11 14)-Positive Relapsed or Refractory Multiple Myeloma
2018-0192 (XmAb13676): A Phase 1 Multidose Study to Evaluate the Safety and Tolerability of XmAb13676 in Patients with CD20-Expressing Hematologic Malignancies
2017-1058 (TAK-079): A Phase 1/2a Open-label, Dose-Escalation Study to Investigate the Safety and Tolerability, Efficacy, Pharmacokinetics, and Immunogenicity of TAK-079 Administered Subcutaneously as a Single Agent in Patients With Relapsed/Refractory Multiple Myeloma
2017-1022 (IDd): A Phase 2, Open-Label Study of Ixazomib+Daratumumab+Dexamethasone (IDd) in Relapsed and/or Refractory Multiple Myeloma (RRMM)
2017-1012 (AMG 701): A Phase 1 Open-label Study Evaluating the Safety, Tolerability, Pharmacokinetics, Pharmacodynamics, and Efficacy of AMG 701 in Subjects With Multiple Myeloma
2017-0935 (SAR650984): A Phase 3 randomized, open label, multicenter study assessing the clinical benefit of isatuximab (SAR650984) in combination with bortezomib (Velcade®), lenalidomide (Revlimid®) and dexamethasone versus bortezomib, lenalidomide and dexamethasone in patients with newly diagnosed multiple myeloma not eligible for transplant
2017-0618 (CC-92480 +Dex in R/R MM): A Phase I Multicenter, Open-label study to assess the Safety, Pharmacokinetics and Preliminary Efficacy of CC-92480 in combination with Dexamethasone in Subjects with Relapsed and Refractory Multiple Myeloma
2017-0408 (CyBorD): A Randomized Phase 3 Study to Evaluate the Efficacy and Safety of Daratumumab in Combination with Cyclophosphamide, Bortezomib and Dexamethasone (CyBorD) Compared With CyBorD Alone in Newly Diagnosed Systemic AL Amyloidosis
2017-0243 (AL AMY): A Safety Study of Daratumumab, Ixazomib, and Dexamethasone in AL Amyloidosis
2017-0024 (MIK665 (Mcl-1) inhibitor: Phase I open label, multi-center study to characterize the safety, tolerability and pharmacokinetics of intravenously administered MIK665, a Mcl-1 inhibitor, in patients with refractory or relapsed lymphoma or multiple myeloma
2016-0225 (c-Met Inh): A Phase I/II Study of the c-Met Inhibitor Cabozantinib as a Targeted Strategy to Reverse Resistance to the Proteasome Inhibitor Carfilzomib in Refractory Multiple Myeloma
2014-0729 (Elotuzumab + Lenalidomide): Phase II Study of the combination of Elotuzumab with Lenalidomide as Maintenance Therapy post Autologous Stem Cell Transplant in Patients with Multiple Myeloma
NCI10076 (AM232): A Phase 1 Dose-Escalation and Exploratory Dose Expansion Study of AMG 232 in Combination with Carfilzomib, Lenalidomide, and Dexamethasone in Relapsed and/or Refractory Myeloma
Lab10-0774 : Genome Wide Admixture Scan of Multiple Myeloma in African-Americans